Intravenous therapy and vein access sit at the operational core of modern medicine. From routine fluid administration in a community hospital to continuous insulin delivery at home and biologic infusions for cancer patients, IV systems underpin an enormous share of clinical care globally. Rising chronic disease burden, aging populations, and a persistent shift toward outpatient and home-based treatment are all converging to make reliable, precise, and safe vascular access more critical than ever. At the same time, regulators, payers, and hospital systems are demanding smarter, safer devices — creating both pressure and opportunity for manufacturers.
The global IV therapy and vein access market reflects that scale. North America alone is projected to grow from $19.3 billion in 2026 to $26.5 billion by 2031, at a 6.5% CAGR. Europe, the second-largest region, is forecast to reach $17.1 billion by 2031 (5.6% CAGR), while Asia-Pacific leads on growth pace, expanding from $12.4 billion to $18.1 billion at a 7.9% CAGR over the same period. Across product categories, specialized infusion pumps command a 2025 market value of $7,969.3 million growing at 9.3% CAGR, and peripheral IV catheters represent a $5,998.7 million segment growing at 6.2% CAGR.
Behind these numbers are companies competing on product breadth, software integration, infection control credentials, and geographic reach. The ten companies profiled below represent a cross-section of that competitive landscape — spanning dedicated vascular access specialists to diversified healthcare conglomerates and technology-focused niche players.
Market Context: Segments and Regional Dynamics
Among product categories, insulin infusion pumps are the fastest-growing specialized pump type, with a 2025 market value of $4,064.4 million and a 10.3% CAGR, fueled largely by the rapid adoption of automated insulin delivery systems. Ambulatory and disposable infusion pumps ($1,182.6 million, 8.7% CAGR) reflect the structural shift toward home and outpatient oncology and pain management infusion. Peripheral IV catheters represent the most broadly deployed vein access product at $5,998.7 million, while central venous catheters ($3,152.5 million, 7.6% CAGR) serve chemotherapy, parenteral nutrition, and critical care. Premixed drug IV solutions, at $3,212.9 million, are growing steadily at 5.3% CAGR as pharmacy automation and medication error reduction remain institutional priorities.
Geographically, the U.S. dominates as a single country market, projected to grow from $16.1 billion in 2026 to $22.3 billion in 2031 at 6.7% CAGR. Germany leads Europe at $3.4 billion in 2026 with a 6.7% CAGR. In Asia-Pacific, China ($4.5 billion in 2026, 8.4% CAGR) and India (9.6% CAGR) are the standout growth markets, driven by government healthcare modernization programs such as China's Healthy China 2030 initiative and India's emerging role as a manufacturing hub attracting major multinationals. Within North America, home-based infusion is the fastest-growing application segment at an 8.2% CAGR from 2026 to 2031, underlining the structural importance of portable, connected, and long-duration vascular access solutions.
Top 10 Companies in the Intravenous (IV) Therapy and Vein Access Market
1. AngioDynamics
• Headquarters: Latham, New York, U.S.
• Founded: 1988
• Revenue: $320.1 million (FY2025)
• Employees: 632
• Focus: Vascular access, peripheral vascular intervention, oncology, surgical technologies
AngioDynamics is a focused medical device company operating across vascular access and minimally invasive oncology. In 2024 it received FDA 510(k) clearance for both the Auryon XL Catheter for peripheral arterial disease and the AlphaVac F1885 System for pulmonary embolism. A distribution partnership with Cardiva extended its vascular access footprint into Spain and Portugal. The company's Med Tech segment posted 19.0% growth, and disciplined operational management expanded gross margins by 300 basis points to 53.9%.
2. Baxter
• Headquarters: Deerfield, Illinois, U.S.
• Founded: 1931
• Revenue: $11,244 million (2025)
• Employees: 37,500
• Focus: IV solutions, parenteral nutrition, infusion pumps and accessories, vein access products
Baxter is one of the most comprehensive IV therapy companies globally, with product lines spanning general and specialty IV solutions, infusion delivery systems, and vascular access. Its SIGMA Spectrum infusion system and Clinimix parenteral nutrition solutions are established platforms across hospital and home settings. The company is investing in digital infusion technologies and expanding into outpatient care, while continuing to develop device innovations targeting specific patient populations including elderly and pediatric groups.
3. Cardinal Health
• Headquarters: Dublin, Ohio, U.S.
• Founded: 1979
• Revenue: $222,578 million (FY2024)
• Employees: 57,700
• Focus: Medical products distribution, pharmaceutical and specialty solutions, at-home solutions, vascular access and infusion therapy products
Cardinal Health operates at an intersection of healthcare distribution and direct medical product supply. Its vascular access and infusion portfolio is embedded within a broader healthcare supply chain business serving hospitals and home care providers. Recent acquisitions include a 73% stake in GI Alliance and the purchase of Advanced Diabetes Supply Group, deepening its specialty and direct-to-patient capabilities. Excluding a large contract expiration, FY2025 revenue grew 18%, with non-GAAP operating earnings rising 15%.
4. ICU Medical Inc.
• Headquarters: San Clemente, California, U.S.
• Founded: 1984
• Revenue: $2,231.2 million (FY2025)
• Employees: 13,000
• Focus: IV pumps, infusion therapy, vascular access, IV sets, needle-free connectors, sterile IV solutions, pharmacy compounding systems
ICU Medical is a dedicated infusion therapy company covering the full product chain from IV solutions and pumps to vascular access and pharmacy compounding. Its Plum 360 infusion system earned the Best in KLAS designation for smart pump EMR integration, and FDA 510(k) clearance for the Plum Duo pump with LifeShield safety software reinforces its position in hospital-grade infusion safety. A joint venture with Otsuka Pharmaceutical Factory is strengthening IV solutions manufacturing capacity across North America.
5. Insulet Corp.
• Headquarters: Acton, Massachusetts, U.S.
• Founded: 2000
• Revenue: $2.71 billion (FY2025)
• Employees: 5,400
• Focus: Omnipod tubeless insulin delivery systems, automated insulin delivery, drug delivery
Insulet is the market leader in tubeless wearable insulin pump technology, with its Omnipod 5 Automated Insulin Delivery System now cleared for adults with type 2 diabetes — a significant expansion of its addressable market. Compatibility with Dexcom G6, G7, and Abbott FreeStyle Libre 2 Plus sensors broadens its ecosystem integration. International rollout is active across Australia, Canada, and multiple European markets. Acquisitions of technology assets from Automated Glucose Control LLC and Bigfoot Biomedical further deepen its AID technology base.
6. IRadimed Corp.
• Headquarters: Orlando, Florida, U.S.
• Founded: 2004
• Revenue: $83.8 million (FY2025)
• Employees: 166
• Focus: MRI-compatible IV infusion pump systems, MRI-compatible patient vital signs monitoring, proprietary IV tubing sets and accessories
IRadimed occupies a defensible niche as the sole provider of non-magnetic IV infusion pump systems and patient vital signs monitoring systems designed for use during MRI procedures. In 2025, the company received FDA 510(k) clearance for the next-generation MRidium 3870 and completed a move to a new Orlando manufacturing facility to support wider commercialization in 2026. With approximately 13,098 systems sold, IRadimed has established meaningful barriers to entry in this specialized segment and reported record revenues in FY2025.
7. Medtronic
• Headquarters: Dublin, Ireland
• Founded: 1949
• Revenue: $33,537 million (FY2024)
• Employees: 95,000
• Focus: Diabetes and insulin delivery systems, implantable infusion pumps, catheters and vein access devices, continuous glucose monitoring, cranial and spinal technologies
Medtronic participates in the IV therapy and vein access market primarily through its diabetes division and implantable pump portfolio. The MiniMed 780G integrated system, extended-wear infusion sets allowing up to seven days of continuous use, and the FDA-approved Simplera Sync CGM sensor reflect active development in closed-loop insulin delivery. The acquisition of EOFlow, maker of the tubeless EOPatch wearable insulin device, positions Medtronic as a more direct competitor in the wearable pump segment. Annual R&D investment of approximately $2.7 billion sustains its broad pipeline.
8. Pfizer Inc.
• Headquarters: New York City, New York, U.S.
• Founded: 1849
• Revenue: $62,579 million (FY2025)
• Employees: 75,000
• Focus: Sterile injectables, hospital products, anti-infectives, oncology, specialty medicines, vaccines
Pfizer's relevance to IV therapy centers on its sterile injectables and hospital products divisions, which supply premixed IV drugs — including antibiotics, analgesics, and oncology agents — administered through infusion systems worldwide. The acquisition of Seagen substantially expanded its oncology drug portfolio, feeding demand for IV administration infrastructure. The European Commission approved EMBLAVEO (aztreonam-avibactam) for serious infections in 2025, adding to its IV anti-infective lineup. Excluding COVID-19 products, Pfizer's core revenue grew 6% operationally in FY2025.
9. B. Braun SE
• Headquarters: Melsungen, Hessen, Germany
• Founded: 1839
• Revenue: $10,627.5 million (2025)
• Employees: 66,821
• Focus: IV solutions and fluid therapy, infusion pumps and accessories, peripheral and central vascular access devices, parenteral nutrition, IV administration sets
B. Braun is one of the oldest and most globally established players in IV therapy, with a product range that covers nearly every category in the market — from PIVCs, PICCs, and CVCs to large volume pumps, syringe pumps, and parenteral nutrition solutions. Its Infusomat Space and Perfusor Space infusion platforms are widely deployed across European hospitals. The company maintains operations across North America, Asia-Pacific, and Europe, with its primary commercial strength in the European region.
10. Cook Medical Inc.
• Headquarters: Bloomington, Indiana, U.S.
• Founded: 1963
• Employees: 12,000
• Focus: Central venous catheters, peripherally inserted central catheters, critical care, interventional radiology, medical devices
Cook Medical is a privately held device manufacturer with a market presence spanning 135 countries. Within IV therapy and vein access, its focus falls on central venous access, with its Spectrum line of CVCs and PICCs impregnated with minocycline and rifampin — a direct response to the infection prevention priorities codified in the WHO's 2024 global guideline on bloodstream infection prevention. This antimicrobial approach positions Cook Medical within one of the more clinically demanding segments of the vascular access market.
Conclusion
The IV therapy and vein access market is not a single product category but a layered ecosystem of infusion systems, consumables, vascular access devices, and pharmaceutical solutions — each with its own growth trajectory, clinical drivers, and competitive dynamics. The companies profiled here reflect that diversity, ranging from pure-play insulin pump specialists like Insulet and IRadimed to broad-base medical device manufacturers like Baxter, B. Braun, and ICU Medical, and pharmaceutical anchors like Pfizer. Their collective investments in smart pump integration, antimicrobial device design, wearable delivery systems, and outpatient infrastructure are defining the direction of the market.
Looking ahead, the most consequential competitive battlegrounds will likely be home-based infusion, automated insulin delivery, and AI-enabled infusion management — areas where software, connectivity, and clinical workflow integration matter as much as device hardware. Asia-Pacific, led by China and India, adds a geographical dimension that will increasingly influence manufacturing strategy and market entry priorities. For buyers, distributors, and healthcare systems, understanding where each major company is positioned across these dimensions is essential to anticipating supply partnerships, procurement choices, and clinical adoption patterns over the next five years.
Learn More and Take Action:
Consider becoming a member of the BCC Research library and gain access to our full catalog of market research reports in your industry. Not seeing what you are looking for? We offer custom solutions too, including our new product line: Custom Intelligence Services.
Contact us today to find out more.
